Hoya Corp
Hoya Corp maintains a strong liquidity position, with a current ratio of 5.07 and cash and equivalents amounting to ¥525.16 billion, significantly exceeding its total liabilities of ¥235.87 billion. The company's debt-to-equity ratio is low at 0.03, indicating a conservative capital structure with minimal reliance on debt financing. This liquidity profile supports operational flexibility and provides a buffer against short-term financial shocks. In terms of profitability, Hoya Corp's return on equity (ROE) of 5.9% and return on assets (ROA) of 4.74% are in line with industry norms for medical equipment and supplies firms. The company's operating income of ¥52.34 billion and net income of ¥57.09 billion reflect strong margins, supported by its high gross profit of ¥170.07 billion on total revenue of ¥196.82 billion. These metrics suggest efficient cost management and pricing power in its core markets. Hoya Corp's revenue is concentrated in its core segments, with the ophthalmic business being the primary contributor. The company's geographic exposure is primarily in Japan, with a growing presence in North America and Europe. However, the input data does not provide specific revenue breakdowns by segment or region. The company's growth trajectory is positive, with a strong operating cash flow of ¥222.80 billion and free cash flow of ¥55.78 billion. Capital expenditures of ¥41.07 billion indicate ongoing investment in production and R&D capabilities. Analysts project a mean price target of ¥29,547.06, with a median of ¥30,000.00, suggesting confidence in the company's future performance. Hoya Corp's risk assessment indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains stable. The absence of dilution potential and the low debt-to-equity ratio suggest that the company is not under pressure to issue new shares or take on additional debt in the near term. Recent events, including analyst estimates and price targets, indicate a generally positive outlook from the investment community. The mean recommendation of 1.78, with 6 strong-buy ratings and 10 buy ratings, reflects strong investor confidence in Hoya Corp's future prospects.
Business. Hoya Corp is a Japanese multinational company that designs, develops, and sells ophthalmic products, medical devices, and optical components, primarily generating revenue through the sale of contact lenses, intraocular lenses, and optical systems.
Classification. Hoya Corp is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.
- Hoya Corp maintains a strong liquidity position with a current ratio of 5.07 and significant cash reserves.
- The company's profitability metrics, including ROE of 5.9% and ROA of 4.74%, are in line with industry norms.
- Hoya Corp's conservative capital structure, with a debt-to-equity ratio of 0.03, supports financial stability.
- Analysts project a positive outlook, with a mean price target of ¥29,547.06 and a median of ¥30,000.00.
- The company faces low liquidity and dilution risks, with no immediate filing-based flags.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.